Lawsuit Overview - BioAge Labs is facing a class-action lawsuit from shareholders alleging the company misled investors about the safety and prospects of its key drug candidate, azelaprag, before its IPO [1][2] - The lawsuit claims BioAge's IPO offering documents contained "materially false and/or misleading" statements regarding the STRIDES Phase 2 clinical trial for azelaprag [2] - The company raised $227.7 million by selling 12.65 million shares at $18 each in its September 2024 IPO [2] Clinical Trial Issues - BioAge presented the STRIDES trial as free of safety concerns and predicted positive results, but halted the trial in December 2024 after participants experienced elevated liver enzymes [3] - The trial discontinuation caused BioAge's stock to plummet over 76%, dropping from the $18 IPO price to around $5.82 per share [4] Legal Allegations - Shareholders accuse BioAge and certain executives of violating the Securities Act of 1933 by making false statements in IPO documents [4] - The close timing between the IPO and trial discontinuation raises questions about the company's pre-IPO disclosures [5] Financial Impact - BioAge's stock price dropped significantly following the trial discontinuation announcement, with shares trading around $5.82 compared to the $18 IPO price [4]

Core Viewpoint - A class action lawsuit has been filed against BioAge Labs, Inc. regarding allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that BioAge and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Shareholders who purchased or acquired BioAge securities during the Class Period have until March 10, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Company Events - BioAge conducted its initial public offering (IPO) on September 26, 2024, selling 12.65 million shares at a price of $18.00 per share [3]. - On December 6, 2024, BioAge announced the discontinuation of the STRIDES Phase 2 study of its investigational drug candidate azelaprag due to observed liver transaminitis in some subjects [3]. Group 3: Stock Price Impact - Following the announcement regarding the discontinuation of the study, BioAge's stock price fell by $15.44 per share, representing a decline of 76.85%, closing at $4.65 per share on December 9, 2024 [4].

Group 1 - BioAge Labs, Inc. is facing a class action lawsuit, which has been notified to investors by Levi & Korsinsky [1] - The lawsuit is related to potential violations of securities laws, indicating possible misrepresentation or omission of material facts [1] - Investors are urged to be aware of the upcoming deadline to participate in the class action [1] Group 2 - The class action lawsuit highlights concerns regarding the company's financial disclosures and overall governance practices [1] - This legal action may impact investor confidence and the company's stock performance in the near term [1] - The outcome of the lawsuit could have significant implications for BioAge Labs' operational strategies and market positioning [1]

Core Viewpoint - Investors with significant losses in BioAge Labs, Inc. have the opportunity to lead a securities fraud class action lawsuit against the company due to alleged misleading statements regarding clinical trials and safety concerns [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that BioAge failed to disclose potential liver transaminitis from previous clinical Phase 1 trials and preclinical toxicology studies [3]. - It is claimed that there were safety concerns with the ongoing STRIDES clinical trial that were not communicated to investors [3]. - The company allegedly overstated the likelihood of completing the STRIDES study and the potential of a second Phase 2 clinical trial involving azelaprag and semaglutide for treating obesity in individuals aged 18 and older [3]. - Defendants' positive statements about the company's business and prospects were said to be materially misleading and lacked a reasonable basis [3]. Group 2: Participation Information - Investors who suffered losses in BioAge Labs, Inc. are encouraged to contact the Law Offices of Howard G. Smith before March 10, 2025, to participate in the ongoing lawsuit [2][4]. - Individuals may retain counsel of their choice or remain absent members of the class action without taking any immediate action [5].

Core Viewpoint - A class action lawsuit has been filed against BioAge Labs, Inc. (BIOA), with a deadline of March 10, 2025, for individuals to join the action [1] Company Summary - The lawsuit indicates potential legal challenges for BioAge Labs, Inc., which may impact its financial standing and market perception [1] - The firm is currently facing scrutiny that could affect its operations and investor confidence [1] Industry Summary - The filing of class action lawsuits in the biotech sector highlights ongoing legal risks that companies in this industry may encounter [1] - Such legal actions can lead to increased regulatory scrutiny and may influence investment decisions within the biotech industry [1]

Core Viewpoint - Shareholders of BioAge Labs, Inc. (BIOA) who have incurred losses are encouraged to contact Levi & Korsinsky regarding a pending class action lawsuit [1] Group 1 - The class action is aimed at addressing the financial losses suffered by shareholders of BioAge Labs, Inc. [1] - The law firm Levi & Korsinsky is representing the interests of the affected shareholders [1] - The announcement highlights the potential for legal recourse for investors who believe they have been wronged [1]

NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc. Investors have until March 10, 2025, to ask the Court to be appointed to lead the case ...

Class Action Filed Against BioAge Labs, Inc. (BIOA) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky ...

BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! ...

BIOA DEADLINE: The March 10 BioAge Labs Class Action Deadline is Approaching - Contact BFA Law if You Suffered Losses ...